Drug
Treprostinil
Status:
Phase 3
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Inhaled Drug
Funder Type:
Industry
Drug Details
Inhaled treprostinil is an inhaled medication approved for the treatment of pulmonary arterial hypertension in World Health Organization (WHO) Group 1 patients. Inhaled treprostinil is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels. Inhaled treprostinil was approved for PAH by the United States Food and Drug Administration (FDA) in 2009 and for PH-ILD in 2021.
Study Purpose
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.